Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

The two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, were
licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then …

Background A single-group, phase 1–2 study indicated that eltrombopag improved the
efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin …

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for
the evaluation, diagnosis, and management of patients with MDS based on a review of …

RNA modification has recently become a significant process of gene regulation, and the
methyltransferase-like (METTL) family of proteins plays a critical role in RNA modification …

Background Anti-programmed cell death 1 (PD-1) and anti-programmed cell death ligand 1
(PD-L1) antibodies are novel immunotherapies for cancer that can induce immune-related …

Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the
introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for …

Aplastic Anemia | New England Journal of Medicine Skip to main content The New England
Journal of Medicine homepage Advanced Search SEARCH The New England Journal of …

Patients with severe aplastic anemia (SAA) are either treated with bone marrow transplant
(BMT) or immunosuppression (IST) depending on their age, comorbidities, and available …